Skip to main content
Top
Published in: International Journal of Hematology 4/2015

01-04-2015 | Original Article

The International Immune Tolerance Induction Study and its follow-up study on Japanese hemophilia A patients with inhibitors

Authors: Akira Yoshioka, Eizaburo Ishii, Tamaki Ueno, Ikuya Usami, Masao Kobayashi, Ryoji Kobayashi, Manabu Sotomatsu, Akira Shirahata, Takashi Suzuki, Masashi Taki, Yasushi Ishida, Tadashi Matsushita, Midori Shima, Keiji Nogami, Michio Sakai, Hisato Kigasawa, Katsuyuki Fukutake

Published in: International Journal of Hematology | Issue 4/2015

Login to get access

Abstract

The International Immune Tolerance Induction (I-ITI) Study in hemophilia A patients with inhibitors included 16 Japanese patients among a total of 115 test subjects. The results within this group of Japanese patients were 11 cases of I-ITI off-study, three cases of I-ITI on-study, and two cases of tolerance on prophylaxis. There was no significant difference in success rate between the low-dose and high-dose groups (Study I). Successively, independent follow-up survey in Japan was conducted in 14 cases, with consent (Study II). Ten cases were off-study at the end of the I-ITI Study. Of these 10 cases, seven of seven successful cases remained clinical successes at the end of the follow-up study, one partial success became a full success while a second relapsed, and one failure was subsequently evaluated as a partial success. Four cases that were on-study at the end of I-ITI Study were classified as three successes and one failure at the end of the follow-up study. As a result, the status at the end of follow-up study was: 11 ITI successes (78.6 %); one partial success; one failure; and one relapse. Thus, the ITI follow-up study was helpful in providing a long-term prognostic determination of inhibitors.
Literature
1.
go back to reference Hay CRM, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012;119:1335–44.CrossRefPubMed Hay CRM, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012;119:1335–44.CrossRefPubMed
2.
go back to reference DiMichele DM, Kroner B. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Haemostasis. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society on Thromboses and Haemostasis. Haematologica. 2000;85(Suppl. 10):40–2.PubMed DiMichele DM, Kroner B. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Haemostasis. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society on Thromboses and Haemostasis. Haematologica. 2000;85(Suppl. 10):40–2.PubMed
3.
go back to reference Astermark J. Genetic and environmental risk factors for inhibitor development. In: Lee C, Berntorp E, Hoots K, editors. Textbook of hemophilia. 2nd ed. Chichester: Wiley-Blackwell; 2010. p. 57–61.CrossRef Astermark J. Genetic and environmental risk factors for inhibitor development. In: Lee C, Berntorp E, Hoots K, editors. Textbook of hemophilia. 2nd ed. Chichester: Wiley-Blackwell; 2010. p. 57–61.CrossRef
4.
go back to reference DiMichele Hay CRM. The international immune tolerance study: a multicenter prospective randomized trial in progress. J Thromb Haemost. 2006;4:2271–3000.CrossRefPubMed DiMichele Hay CRM. The international immune tolerance study: a multicenter prospective randomized trial in progress. J Thromb Haemost. 2006;4:2271–3000.CrossRefPubMed
5.
go back to reference Astermark J, Morado M, Rocino A, van den Berg HM, von Depka M, Gringeri A, et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia. 2006;12:363–71.CrossRefPubMed Astermark J, Morado M, Rocino A, van den Berg HM, von Depka M, Gringeri A, et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia. 2006;12:363–71.CrossRefPubMed
Metadata
Title
The International Immune Tolerance Induction Study and its follow-up study on Japanese hemophilia A patients with inhibitors
Authors
Akira Yoshioka
Eizaburo Ishii
Tamaki Ueno
Ikuya Usami
Masao Kobayashi
Ryoji Kobayashi
Manabu Sotomatsu
Akira Shirahata
Takashi Suzuki
Masashi Taki
Yasushi Ishida
Tadashi Matsushita
Midori Shima
Keiji Nogami
Michio Sakai
Hisato Kigasawa
Katsuyuki Fukutake
Publication date
01-04-2015
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 4/2015
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-015-1734-z

Other articles of this Issue 4/2015

International Journal of Hematology 4/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine